Size | Price | Stock | Qty |
---|---|---|---|
1mg |
|
||
5mg |
|
||
10mg |
|
||
Other Sizes |
|
ln Vitro |
BMS-587101 is a moderately effective LFA-1-mediated T cell proliferation agent with an IC50 of 20 nM in human HUVEC cells. BMS-587101 inhibits LFA-1-mediated coupling of T cells to endothelial cells. BMS-587101 showed inhibitory activity in mouse splenocytes and mouse ICAM-1 expressing cell line bEND with an IC50 of 150 nM[1] .
|
---|---|
ln Vivo |
BMS-587101 (0.1 mg/kg, 1.0 mg/kg, and 10 mg/kg; route; twice daily) administration significantly reduced eosinophil recruitment in a mouse ovalbumin-induced lung conditioning paradigm [1].
|
References |
|
Molecular Formula |
C26H20CL2N4O4S
|
---|---|
Molecular Weight |
555.43
|
Exact Mass |
554.058
|
CAS # |
509083-77-6
|
PubChem CID |
11635371
|
Appearance |
Off-white to light yellow solid powder
|
Density |
1.6±0.1 g/cm3
|
Boiling Point |
748.4±70.0 °C at 760 mmHg
|
Flash Point |
406.4±35.7 °C
|
Vapour Pressure |
0.0±2.6 mmHg at 25°C
|
Index of Refraction |
1.738
|
LogP |
3.88
|
Hydrogen Bond Donor Count |
1
|
Hydrogen Bond Acceptor Count |
7
|
Rotatable Bond Count |
5
|
Heavy Atom Count |
37
|
Complexity |
975
|
Defined Atom Stereocenter Count |
2
|
SMILES |
CN1C(=O)N(C(=O)[C@]12CN(C[C@H]2C3=CC=C(C=C3)C#N)CC4=CC(=CS4)C(=O)O)C5=CC(=CC(=C5)Cl)Cl
|
InChi Key |
NXNKJLOEGWSJGI-BKMJKUGQSA-N
|
InChi Code |
InChI=1S/C26H20Cl2N4O4S/c1-30-25(36)32(20-8-18(27)7-19(28)9-20)24(35)26(30)14-31(11-21-6-17(13-37-21)23(33)34)12-22(26)16-4-2-15(10-29)3-5-16/h2-9,13,22H,11-12,14H2,1H3,(H,33,34)/t22-,26+/m0/s1
|
Chemical Name |
5-[[(5S,9R)-9-(4-cyanophenyl)-3-(3,5-dichlorophenyl)-1-methyl-2,4-dioxo-1,3,7-triazaspiro[4.4]nonan-7-yl]methyl]thiophene-3-carboxylic acid
|
Synonyms |
BMS587101; BMS 587101; BMS-587101
|
HS Tariff Code |
2934.99.9001
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
DMSO : ~260 mg/mL (~468.11 mM)
|
---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 6.5 mg/mL (11.70 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 65.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly.  (Please use freshly prepared in vivo formulations for optimal results.) |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 1.8004 mL | 9.0020 mL | 18.0041 mL | |
5 mM | 0.3601 mL | 1.8004 mL | 3.6008 mL | |
10 mM | 0.1800 mL | 0.9002 mL | 1.8004 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.